Detalhe da pesquisa
1.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Lancet Oncol
; 25(4): 463-473, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467131
2.
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Am J Hematol
; 97(2): E47-E51, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779028
3.
Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence.
EMBO J
; 31(6): 1494-505, 2012 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22266796
4.
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.
Mol Cell
; 30(1): 61-72, 2008 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18406327
5.
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.
EMBO J
; 27(7): 1017-28, 2008 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18354499
6.
Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine.
Mol Cell Biol
; 25(21): 9576-85, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16227606
7.
Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.
Pharmacol Res Perspect
; 3(5): e00178, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26516589
8.
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Clin Cancer Res
; 18(11): 3163-9, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496272
9.
Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation.
Mol Cell Biol
; 28(20): 6234-47, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18710942